(PLSE) Pulse Biosciences - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 958m USD | Total Return: 51.7% in 12m

Medical Devices, Ablation Systems, Surgical Tools, Electronic Platforms
Total Rating 45
Safety 70
Buy Signal -0.32
Medical Instruments & Supplies
Industry Rotation: -3.8
Market Cap: 958M
Avg Turnover: 5.71M USD
ATR: 6.55%
Peers RS (IBD): 92.5
Risk 5d forecast
Volatility86.1%
Rel. Tail Risk-19.0%
Reward TTM
Sharpe Ratio0.70
Alpha26.65
Character TTM
Beta0.957
Beta Downside-0.413
Drawdowns 3y
Max DD55.90%
CAGR/Max DD1.53
EPS (Earnings per Share) EPS (Earnings per Share) of PLSE over the last years for every Quarter: "2021-03": -0.71, "2021-06": -0.58, "2021-09": -0.48, "2021-12": -0.52, "2022-03": -0.58, "2022-06": -0.44, "2022-09": -0.49, "2022-12": -0.25, "2023-03": -0.26, "2023-06": -0.22, "2023-09": -0.19, "2023-12": -0.2167, "2024-03": -0.1837, "2024-06": -0.1991, "2024-09": -0.2076, "2024-12": -0.3124, "2025-03": -0.2502, "2025-06": -0.28, "2025-09": -0.29, "2025-12": -0.2572,
EPS CAGR: 101.06%
EPS Trend: 53.0%
Last SUE: 0.50
Qual. Beats: 0
Revenue Revenue of PLSE over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0.574, 2021-12: 0.844, 2022-03: 0.444, 2022-06: 0.265, 2022-09: 0, 2022-12: -0.009, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 1.74, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 1.664, 2025-03: 0.832, 2025-06: 0, 2025-09: 0.086, 2025-12: 0.264,
Rev. CAGR: -12.95%
Rev. Trend: 15.0%
Last SUE: 0.10
Qual. Beats: 0
Warnings

Share dilution 15.4% YoY - potential capital distress

Altman Z'' -15.00 < 1.0 - financial distress zone

volatile

Tailwinds

No distinct edge detected

Description: PLSE Pulse Biosciences

Pulse Biosciences, Inc. (PLSE) is a bioelectric medicine company. It develops and commercializes the nPulse System, a Nanosecond Pulsed-Field Ablation (NPA) platform.

The companys product offerings include devices for treating benign skin lesions, soft tissue ablation, and cardiac applications such as atrial fibrillation. The medical device sector is characterized by lengthy regulatory approval processes.

Pulse Biosciences business model focuses on developing and commercializing medical devices utilizing its proprietary NPA technology. This often involves significant research and development investments.

To gain a deeper understanding of PLSEs financial performance and market position, consider exploring its detailed analytics on ValueRay.

Headlines to Watch Out For
  • FDA approval for new medical devices drives revenue growth
  • Clinical trial results impact product adoption and sales
  • Reimbursement policies for novel treatments affect market access
  • Manufacturing costs and supply chain efficiency influence profitability
  • Competition from established medical device companies limits market share
Piotroski VR‑10 (Strict) 0.0
Net Income: -72.8m TTM > 0 and > 6% of Revenue
FCF/TA: -0.57 > 0.02 and ΔFCF/TA -29.11 > 1.0
NWC/Revenue: 6.39k% < 20% (prev 6.57k%; Δ -186.8% < -1%)
CFO/TA -0.56 > 3% & CFO -54.1m > Net Income -72.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.53 > 1.5 & < 3
Outstanding Shares: last quarter (67.4m) vs 12m ago 15.41% < -2%
Gross Margin: -14.04% > 18% (prev 0.0%; Δ -1.40k% > 0.5%)
Asset Turnover: 1.03% > 50% (prev 1.26%; Δ -0.22% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.79 (Total Current Assets 83.4m - Total Current Liabilities 7.92m) / Total Assets 96.1m
B: -4.82 (Retained Earnings -463.3m / Total Assets 96.1m)
C: -0.65 (EBIT TTM -74.0m / Avg Total Assets 114.3m)
D: -29.97 (Book Value of Equity -463.2m / Total Liabilities 15.5m)
Altman-Z'' Score: -46.38 = D
Beneish M
DSRI: none (Receivables 274k/none, Revenue 1.18m/1.66m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.66 (AQ_t 0.06 / AQ_t-1 0.04)
SGI: 0.71 (Revenue 1.18m / 1.66m)
TATA: -0.19 (NI -72.8m - CFO -54.1m) / TA 96.1m)
Beneish M-Score: cannot calculate (missing components)
What is the price of PLSE shares? As of April 06, 2026, the stock is trading at USD 23.00 with a total of 143,560 shares traded.
Over the past week, the price has changed by +17.17%, over one month by +23.79%, over three months by +57.53% and over the past year by +51.72%.
Is PLSE a buy, sell or hold? Pulse Biosciences has no consensus analysts rating.
What are the forecasts/targets for the PLSE price?
Analysts Target Price 22 -4.3%
Pulse Biosciences (PLSE) - Fundamental Data Overview as of 03 April 2026
P/S = 4473.6816
P/B = 19.4553
Revenue TTM = 1.18m USD
EBIT TTM = -74.0m USD
EBITDA TTM = -73.0m USD
Long Term Debt = 7.53m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.57m USD (from shortTermDebt, last quarter)
Debt = 7.53m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -73.2m USD (from netDebt column, last quarter)
Enterprise Value = 885.0m USD (958.2m + Debt 7.53m - CCE 80.7m)
 Interest Coverage Ratio = unknown (Ebit TTM -74.0m / Interest Expense TTM 0.0)
 EV/FCF = -16.26x (Enterprise Value 885.0m / FCF TTM -54.4m)
FCF Yield = -6.15% (FCF TTM -54.4m / Enterprise Value 885.0m)
 FCF Margin = -4.61k% (FCF TTM -54.4m / Revenue TTM 1.18m)
 Net Margin = -6.16k% (Net Income TTM -72.8m / Revenue TTM 1.18m)
 Gross Margin = -14.04% ((Revenue TTM 1.18m - Cost of Revenue TTM 1.35m) / Revenue TTM)
Gross Margin QoQ = -96.59% (prev none%)
Tobins Q-Ratio = 9.21 (Enterprise Value 885.0m / Total Assets 96.1m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 7.53m)
Taxrate = 21.0% (US default 21%)
NOPAT = -58.5m (EBIT -74.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.53 (Total Current Assets 83.4m / Total Current Liabilities 7.92m)
Debt / Equity = 0.09 (Debt 7.53m / totalStockholderEquity, last quarter 80.7m)
 Debt / EBITDA = 1.00 (negative EBITDA) (Net Debt -73.2m / EBITDA -73.0m)
 Debt / FCF = 1.34 (negative FCF - burning cash) (Net Debt -73.2m / FCF TTM -54.4m)
 Total Stockholder Equity = 99.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.68% (Net Income -72.8m / Total Assets 96.1m)
RoE = -73.46% (Net Income TTM -72.8m / Total Stockholder Equity 99.1m)
RoCE = -69.45% (EBIT -74.0m / Capital Employed (Equity 99.1m + L.T.Debt 7.53m))
 RoIC = -59.03% (negative operating profit) (NOPAT -58.5m / Invested Capital 99.1m)
 WACC = 9.28% (E(958.2m)/V(965.8m) * Re(9.35%) + D(7.53m)/V(965.8m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.64%
 [DCF] Fair Price = unknown (Cash Flow -54.4m)
 EPS Correlation: 52.97 | EPS CAGR: 101.1% | SUE: 0.50 | # QB: 0
Revenue Correlation: 15.00 | Revenue CAGR: -12.95% | SUE: 0.10 | # QB: 0
EPS next Year (2026-12-31): EPS=-1.66 | Chg7d=-0.220 | Chg30d=-0.220 | Revisions Net=-1 | Growth EPS=-45.6% | Growth Revenue=+1016.1%
External Resources
Dataroma Stockcircle